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Abstract
Introduction: Few studies have addressed the decision-making process of antibiotic therapy (AT) in intensive care
unit (ICU) patients.
Methods: In a prospective observational study, all consecutive patients admitted over a one-month period (2004)
to 41 French surgical (n = 22) or medical/medico-surgical ICUs (n = 19) in 29 teaching university and 12 non-
teaching hospitals were screened daily for AT until ICU discharge. We assessed the modalities of initiating AT,
reasons for changes and factors associated with in ICU mortality including a specific analysis of a new AT
administered on suspicion of a new infection.
Results: A total of 1,043 patients (61% of the cohort) received antibiotics during their ICU stay. Thirty percent (509)
of them received new AT mostly for suspected diagnosis of pneumonia (47%), bacteremia (24%), or intra-
abdominal (21%) infections. New AT was prescribed on day shifts (45%) and out-of-hours (55%), mainly by a single
senior physician (78%) or by a team decision (17%). This new AT was mainly started at the time of suspicion of
infection (71%) and on the results of Gram-stained direct examination (21%). Susceptibility testing was performed
in 261 (51%) patients with a new AT. This new AT was judged inappropriate in 58 of these 261 (22%) patients. In
ICUs with written protocols for empiric AT (n = 25), new AT prescribed before the availability of culture results (P =
0.003) and out-of-hours (P = 0.04) was more frequently observed than in ICUs without protocols but the
appropriateness of AT was not different. In multivariate analysis, the predictive factors of mortality for patients with
new AT were absence of protocols for empiric AT (adjusted odds ratio (OR) = 1.64, 95% confidence interval (95%
CI): 1.01 to 2.69), age ≥60 (OR = 1.97, 95% CI: 1.19 to 3.26), SAPS II score >38 (OR = 2.78, 95% CI: 1.60 to 4.84),
rapidly fatal underlying diseases (OR = 2.91, 95% CI: 1.52 to 5.56), SOFA score ≥6 (OR = 4.48, 95% CI: 2.46 to 8.18).
Conclusions: More than 60% of patients received AT during their ICU stay. Half of them received new AT,
frequently initiated out-of-hours. In ICUs with written protocols, empiric AT was initiated more rapidly at the time
of suspicion of infection and out-of-hours. These results encourage the establishment of local recommendations for
empiric AT.
Introduction
Initiation of antibiotic therapy (AT) in intensive care
unit (ICU) patients is a critical issue. The importance of
empiric AT covering all pathogens responsible for infec-
tions has been highlighted on many occasions [1-4]. The
need for urgent AT was also emphasized in a study
demonstrating a 7% increased mortality for each hour of
delayed empiric AT in patients with severe sepsis and
septic shock [5]. The time to the first dose of AT has
been emphasized in the recommendations of the surviv-
ing sepsis campaign [6] and has become a measure of
quality of care in ICU patients [7-9]. The difficulty in
differentiating infectious from noninfectious etiologies in
critically ill patients is also a major driver of antibiotic
prescribing in ICUs leading to the development of new
diagnostic tests [10]. On the other hand, the parsimo-
nious choice of AT drugs has also been stressed to cur-
tail the emergence of resistance and contain the cost
[11,12].
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on appropriateness, while few longitudinal surveillance
studies have analyzed the decision-making process
[1,2,4,13-15]. To more clearly understand AT current
prescribing practices in ICU patients, a prospective mul-
ticenter observational study was performed to describe
the modalities of initiation (frequency, timing) of AT,
the reason for changes (streamline/de-escalate therapy)
and identification of independent factors associated with
mortality in patients receiving new AT during their ICU
stay.
Materials and methods
Participating centers and team organization
This one-month (November 2004) prospective multicen-
ter observational study was conducted in 41 adults sur-
gical (n = 22) or medical/medico-surgical ICUs (n =1 9 )
in 29 teaching university and 12 non-teaching hospitals.
Participating ICUs, volunteers participating in the study,
were widely distributed throughout France. These were
closed units of more than six beds, non-specialized units
(avoiding cardiac and neurosurgical ICUs), with a criti-
cal care specialist and microbiology laboratory on hand
24 hours a day.
Legal organization of day shifts and “out-of-hours”
hours in French ICUs has been previously described
[16]. Briefly, day shifts as defined by law run from Mon-
day to Friday, 8:30 am to 6:29 pm, and Saturday from
8:30 am to 12:59 pm; the remaining period corresponds
to off hours. Overall during the study period, day shifts
accounted for 218 hours (30.2%) in a total of 720 hours
of work.
In these units, day-shift medical teams consisted of a
median of three (range, 1 to 6) senior physicians board
certified in critical care medicine, a median of one
(range, 0 to 3) critical care specialist in training (certi-
fied medical specialist in anesthesiology, or medical spe-
cialty), and a median of two (range, 0 to 5) residents.
During out-of-hours, one critical care specialist (board
certified or in training) was on call on site, either alone
(in 14 ICUs) or with a medical resident.
Study design and patients
In each center, the principal investigator was the senior
critical care specialist leading the team and fully respon-
sible for the ICU. All consecutive adult patients
admitted to the ICU during the study period were eligi-
ble for enrollment. Criteria used for diagnosis, microbio-
logic techniques and the decision to prescribe AT were
left to the physician’s discretion. Ethics Committee
approval for the protocol was obtained. In accordance
with French law, as the study protocol was strictly
observational and did not modify clinical practice, infor-
mation was given to the patients and their familly but
no written informed consent was obtained from our
patients. Approval of the CNIL (Commission Nationale
de l’Informatique et des Libertés) was obtained, ensuring
that patient data were kept confidential according to
French regulations. A Scientific Committee indepen-
dently designed the study and reviewed all data
collected.
Clinical data
For each ICU admission, demographic characteristics,
underlying diseases, severity of illness, and type of
admission were recorded on a standardized report form.
Severity of illness on admission was assessed using the
simplified acute physiology score II (SAPS II score) [17].
Underlying diseases were classified as not ultimately
fatal, ultimately fatal (death expected in <5 years) or
rapidly fatal (in <1 year) according to the McCabe score
[18].
To assess the incidence of AT during the ICU stay,
the patients were classified into four categories: (I)
patients not receiving AT either at the time of admis-
sion, or during their ICU stay; (II) patients suspected of
having bacterial infection and already receiving AT at
the time of admission; (III) patients with known infec-
tion with identification and susceptibility testing of the
pathogen at the time of admission on which AT was
based; (IV) patients receiving new AT for a new suspi-
cion of infection during their ICU stay (Figure 1). This
last subgroup was analyzed specifically. In patients who
developed several infections during their ICU stay, only
the first episode of new AT was considered. A preceding
seven-day course free of antibiotics was required before
considering a new course of AT. Antibiotic prophylaxis
was not analyzed in the current study.
Decision-making process of AT
In each center, the presence and number of empiric AT
protocols were assessed. The period of initiation of AT
was defined by categorizing the week into day shifts and
out-of-hours. The type of prescriber was assessed: fellow
or senior physician (assistant professor, senior critical
care specialist). The individual or team decision (>2
physicians) for initiation of AT was assessed. When
infectious disease specialists were involved in the deci-
sion-making progress, they were considered as a part of
the team. Patients with one of the following diagnoses
were classified as being immunosuppressed: febrile neu-
tropenia, splenectomized patients, cirrhosis, solid organ
transplantation, steroid therapy, and HIV infection [19].
Therapeutic emergencies were defined as septic shock,
hypoxemic pneumonia or multiple organ failure (MOF)
[19]. The sequential organ failure assessment (SOFA)
score was calculated at the time of initiation of AT [20].
The supposed source of infection was recorded.
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recommendations of the French Society for Microbiol-
ogy [21]. Microbiologic results were recorded as part of
the decision-making process for initiation or changes of
AT. The definitions used for the site of infection, true
pathogens, contaminants and commensals were those
recommended by the French Society of Anæsthesiology
and Critical Care Medicine [22]. The following timing
of AT prescription was analyzed: in the absence or
before microbiologic sampling; after microbiologic sam-
pling; on the results of Gram-stained direct examination,
on the results of microbiologic cultures (24 to 48 hours);
on the results of susceptibility testing (Figure 1). In
patients with negative cultures, the decisions were
assessed 48 hours after collection of the samples when
the cultures demonstrated no growth. Apart from adap-
tation to microbiologic results, the other reasons for
antibiotic changes were recorded: clinical worsening,
new site of infection, antibiotic side effect, de-escalation
(withdrawing the non-pivotal antibiotic or switching to
a narrow-spectrum antibiotic) and discontinuation of
aminoglycosides. The quality of antibiotic prescription
(dose, intervals, and so on) according to pharmacoki-
netic/pharmacodynamic criteria was not analyzed.
Patients treated without any microbiologic sampling of
their suspected infection or having their treatment based
only on microbiologic identification without susceptibil-
ity testing were considered to have a low level of micro-
biologic confirmation of infection. In patients undergoing
susceptibility testing of their microbiologic samples,
appropriateness of AT was assessed by the principal
investigator at the end of the therapeutic course. In order
to replicate real life conditions as much as possible, all
positive microbiologic cultures were analyzed [22] but
appropriateness of AT was only considered for true
pathogens. Therapy was judged appropriate if, according
to the susceptibility testing [21], all bacteria considered
true pathogens were targeted by at least one of the drugs
administered. The other cases were classified as inap-
propriate AT. The antibiotic selection was judged appro-
priate or inappropriate on the basis of the culture results
obtained. Considering that severe infections encountered
in ICU cases require emergency AT, the scientific com-
mittee classified the delayed introduction of AT at the
time of susceptibility testing as arbitrary and inadequate
AT. Fungi were excluded from the analysis of appropri-
ateness and antifungal therapy was not considered.
Outcome
All patients were followed from the day of admission
until ICU discharge. Death during ICU stay was
recorded. Links between ICU mortality and clinical fea-
tures of new AT were assessed.
Statistical analysis
Patient characteristics according to AT during their ICU
stay were analyzed. Characteristics of AT were assessed
and their relationships with death were determined.
Patients included in the prospective survey  
N=1,702 
(I) 
No AT during  
 ICU stay  
N=659 (39%) 
(II) 
AT already administered  
at admission  in ICU 
N=483 (28%) 
(III) 
AT prescribed in ICU with  
susceptibility testing available 
N=51 (3%) 
(IV) 
New AT initiated 
 in ICU 
N=509 (30%) 
AT started  
at the results of 
 susceptibility testing 
N=16   
AT started  
at the time of  
suspicion of infection 
N=363  
AT started  
at the results of  
Gram-stained examination 
N=105  
AT started  
at the results of 
 microbiologic identification 
N=25  
Figure 1 Number and proportions of patients included in the study according to their antimicrobial therapy status. During their intensive
care unit stay: (I) Patients never receiving any antimicrobial agents; (II) patients suspected of having bacterial infection and already receiving
antibiotic treatment at the time of admission; (III) patients receiving antibiotic therapy for a known infection with identification and susceptibility
testing of the pathogen at the time of admission; (IV) patients receiving new antibiotic therapy for suspicion of infection during their ICU stay.
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College Station, TX, USA). We assessed that the continu-
ous variables were normaIly distributed using the Shapiro-
Wilk test. Variables were expressed as mean with standard
deviation and range or numbers with proportions. Groups
were compared using the Chi-square test with Yates’ cor-
rection if necessary for qualitative parameters and
ANOVA for quantitative data. Bonferroni correction was
used for multiple comparisons. To identify factors inde-
pendently associated with death, a multivariate stepwise
logistic regression analysis was performed among the fac-
tors found to be significant at the 15% level in univariate
analysis [23]. A backward Wald model was used. The
probability to enter in the model was 0.05 and to remove
0.1. Hosmer-Lemshow goodness of fit Chi-square was
assessed. The median value of the population was used as
a cut-off for quantitative data. Odds-ratio (OR) and their
95% confidence intervals (95% CI) were calculated. Statis-
tical significance was accepted at the 5% level.
Results
Study population
A total of 1,702 patients (Figure 1) was studied. The
mean number of admissions in each unit was 42 ± 21
pts. Overall, 54 ± 30% of patients were admitted for a
medical reason, 9 ± 12% following scheduled surgery,
and 37 ± 25% following emergency surgery.
Overall, 34 ± 21% of patients did not receive any AT
during their ICU stay, 29 ± 21% were already treated at
the time of admission, 4 ± 7% received an AT with
identification and susceptibility testing available at
admission, and 34 ± 16% received new AT (Table 1).
The large variation in the amount of antibiotics used by
the different ICUs is illustrated by Figure 2.
Local organization
Written protocols for empiric AT were available in 25 (61%)
ICUs in accordance with national guidelines and adapted to
local epidemiology, including antibiotic resistance frequen-
cies. These protocols were defined for community-acquired
infections (mainly pneumonia n = 19, intra-abdominal
infections n = 19, meningitis n = 18) and nosocomial infec-
tions (mainly ventilator-associated pneumonia (VAP) n =
21, postoperative intra-abdominal infections n = 16, septic
shock n = 16) with a mean of 6 ± 3 protocols per ICU. No
difference was observed between teaching and non-teaching
hospitals in terms of the availability (63% vs 57%, P = 0.72)
and mean number of protocols (3 ± 3 vs 4 ± 3, P = 0.96).
The number and availability of protocols were similar in
surgical, medical and medico-surgical units.
Decision-making process of antibiotic therapy
Among the 509 patients receiving new AT during their
ICU stay, the main underlying diseases were
immunosuppression (n = 61; 12%), respiratory and car-
diovascular comorbidities (n = 62; 12%), cirrhosis (n =
31; 6%) and scored as ultimately (24%) or rapidly (11%)
fatal. The mean SOFA score at the time of AT prescrip-
tion was 6 ± 5. Therapeutic emergencies were reported
in 42% (n = 215) of cases, including septic shock (n =
122; 24%), MOF (n = 47; 9%) and hypoxemic pneumo-
nia (n = 1 01; 20%) with high SOFA score (11 ± 6; 13 ±
6; 9 ± 6, respectively). The most frequently suspected
sites of infection were lung (n = 241; 47%), bacteremia
(n = 121; 24%), and intra-abdominal (n = 105; 21%).
AT was initiated at the time of suspicion of infection
in 363 cases (71%), based on the results of direct exami-
nation by Gram-stain in 105 cases (21%), on microbiolo-
gic cultures (n = 25; 5%) or susceptibility testing (n =
16; 3%) (Figure 1). New AT was decided on day shifts in
227 cases (45%) and out-of-hours in 282 cases (55%).
New empiric AT was initiated in 213 (76%) patients
out-of hours and in 150 (66%) patients on day shifts (P
= 0.03). Treatment was based on the results of Gram-
stain direct examination in 49 (17%) patients out-of-
hours and in 56 (25%) cases on day shifts (P = 0.055),
on microbiologic cultures in 14 (5%) and 11 (5%)
patients, and on susceptibility testing in 6 (2%) and 10
(4%) patients, respectively. In most cases, the decision to
prescribe AT was made by a single senior physician (n
= 397, 78%, involving a senior critical care specialist (n
= 340; 67%) or an assistant professor (n = 57; 11%)),
and more rarely by the team (n = 87; 17%), or a fellow
(n = 25; 5%).
Among the 215 patients with therapeutic emergencies,
AT was initiated empirically on suspicion of infection in
152 cases (71%), in 195 (91%) at the time of the Gram-
stain, on the results of microbiologic cultures in 206
cases (96%) or susceptibility tests in 214 (99.5%).
Among the 121 patients suspected of bacteremia, 86
(71%) of them were treated before Gram-stain examina-
tion, 34 (28%) at the time of pathogen identification and
1 (1%) at the time of susceptibility testing. The AT deci-
sion-making process is shown in Table 2.
No difference in the severity of the cases (assessed by
SAPS II and SOFA scores) was observed according to
the timing of prescription, the type of prescriber, or the
time to initiation of AT.
Role of local protocols on empiric AT
When comparing ICUs with written empiric AT proto-
cols and those without protocols, the proportion of
empiric AT among all antibiotic prescriptions was simi-
lar (33% (305 patients) of the cases per center versus
32% (204 patients), respectively) and severity scores
were similar. The number of patients receiving antibio-
tics in units with written protocols and those without
protocols was similar whenever the number of patients
Montravers et al. Critical Care 2011, 15:R17
http://ccforum.com/content/15/1/R17
Page 4 of 13(12 ± 6 vs 13 ± 5 patients, P = 0.75) or their proportions
(35 ± 19 vs 32 ± 10%, P = 0.56) were considered.
When compared to ICUs without protocols, a higher
proportion of prescriptions was made by fellows in ICUs
with written protocols (48 (14.7%) vs 12 (6.6%) in other
ICUs, respectively, P = 0.01), AT prescriptions were
more frequent at the time of suspicion of infection in
ICUs with protocols (251 (76.7%) vs 112 (61.5%), respec-
tively; P = 0.003) and prescription was more frequent
out-of-hours in the units with a written protocol (192
(59%) vs 90 (49.5%), respectively; P = 0.04).
Discontinuation and changes of empiric AT
Overall, empiric ATs were interrupted in 14 patients
and modified in 163 patients following Gram-stained
direct examination, microbiologic examination and sus-
ceptibility testing. Time of stopping and changes in
empiric AT is summarized in Table 2.
Overall, in 346 (68%) patients no change of the new
AT was made, while 191 changes were observed in 163
(31%) patients: 137 patients (27%) had one AT change,
24 (5%) two changes, and 2 (0.2%) three changes. The
timing of these AT changes is presented in Table 2.
Among these patients with modified AT, changes were
unrelated to microbiologic reasons in 98 (19%) patients
but were linked to clinical deterioration n =2 1( 4 % ) ,t o
new site(s) of infection n = 14 (3%), to interruption of
aminoglycosides n = 36 (7%), to adverse effects n =6
(1%), or to de-escalation therapy n = 40 (8%).
Among the 215 patients with therapeutic emergencies,
changes of AT were reported for the following reasons:
21 (10%) de-escalation, 18 (8%) interruption of
aminoglycosides, 14 (6%) clinical deterioration, 4 (2%)
new site(s) of infection and 2 (1%) adverse events.
New AT in patients with a low level of microbiologic
confirmation of infection
Overall 248 (49%) patients had a low level of microbio-
logic assessment of infection. Eighty (16%) patients
(mean age 55 ± 21) received new AT without any
microbiologic sampling of their suspected infection.
Among these patients with a mean SAPS II score of 33
± 15 on ICU admission, 49 (61%) were admitted for a
medical diagnosis, 26 (33%) for emergency surgery and
5 (6%) for scheduled surgery. Eight (10%) were immuno-
suppressed, 6 (7.5%) had comorbidities and 19 (24%)
had an ultimately or rapidly fatal underlying disease.
Their mean SOFA score was 5 ± 5 and 10 (12.5%) had
signs of therapeutic emergencies. Most of these patients
were suspected of having pulmonary infection (n = 35,
44%) or intra-abdominal infection (n = 14, 18%).
In the remaining 168 cases, AT was continued with
only limited microbiologic confirmation. In 59 (12%)
cases, AT was prolonged and based on microbiologic
identification without susceptibility testing, while 109
(21%) patients had negative cultures. Among these 59
cases with only organisms identification (SAPS II score
o na d m i s s i o no f4 4±1 7a n dS O F As c o r eo f9±6a t
the time of initiation of therapy), therapeutic emergen-
cies were observed in 25 (42%) cases while therapeutic
emergencies were reported in 39 (36%) of the 109 cases
with negative samples (SAPS II score on admission of
3 8±1 7a n dS O F As c o r eo f7±6a tt h et i m eo fi n i t i a -
tion of therapy).
Table 1 Main characteristics of the overall population included according to their antimicrobial therapy status
Parameters No AT in the
ICU
AT on ICU
admission
AT on ICU admission and ST
available
New AT in the
ICU
P
N = 659 (39%) N = 483(28%) N = 51(3%) N = 509(30%)
Age 54 ± 18 59 ± 17 57 ± 18 57 ± 19 <0.001
SAPS II score on admission 33 ± 21 33 ± 18 40 ± 15 41 ± 18 <0.001
Male gender 392 (59%) 323 (67%) 33 (65%) 326 (64%) 0.07
Type of admission
scheduled surgery 145 (22%) 188 (39%) 3 (6%) 36 (7%)
medical 367 (56%) 172 (36%) 28 (55%) 290 (57%) <0.001
emergency surgery 147 (22%) 123 (25%) 20 (39%) 183 (36%)
Underlying disease
Not ultimately fatal 463 (70%) 261 (54%) 37 (73%) 329 (65%)
Ultimately fatal 141 (21%) 175 (36%) 12 (23%) 123 (24%) <0.001
Rapidly fatal 55 (8%) 47 (10%) 2 (10%) 57 (11%)
AT protocols available in the ICU 380 (58%) 321 (66%) 23 (45%) 327 (64%) <0.001
Number of empiric AT protocols
available
3 ± 3 4 ± 4 2 ± 3 4 ± 4 <0.001
Data are presented as mean ± SD or as number (proportion). AT, antibiotic therapy; ICU, intensive care unit; SAPS II, simplified acute physiologic score II; ST,
susceptibility testing. Underlying disease classification according to the McCabe score, see material and methods section.
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Figure 2 Proportions of patients included in the study according to their antimicrobial therapy status. During their intensive care unit
stay in each ICU represented on the vertical axis. In ICUs 1 to 16 no written empiric antibiotic protocol was used while protocols were used in
units 17 to 41. I) patients never receiving any antimicrobial agents; (II) patients suspected of having bacterial infection and already receiving
antibiotic treatment at the time of admission; (III) patients receiving antibiotic therapy for a known infection with identification and susceptibility
testing of the pathogen at the time of admission; (IV) patients receiving new antibiotic therapy for suspicion of infection during their ICU stay.
Table 2 Antimicrobial therapy characteristics according to the timing and level of microbiologic results
AT course
No AT AT started Ongoing AT AT modified AT stopped
Clinical, radiologic or surgical suspicion of infection, N = 509 146 (29%) 363 (71%) - - -
Gram-stained direct examination, N = 509 41 (8%) 105 (21%) 345 (68%) 15 (3%) 3 (1%)
Available, N = 204 (40%) 8 105 73 15 3
Not available, N = 305 (60%) 33 - 272 - 0
Microbiologic identification (24 to 48 hours), N = 509 23 (4%) 25 (5%) 403 (77%) 55 (11%) 3 (1%)
Available, N = 251 (49%) 6 25 162 55 3
Not available, N = 258 (51%) 17 - 241 - 0
Susceptibility testing, N = 509 - 16 (3%) 392 (77%) 93 (18%) 8 (1.8%)
Available, N = 261 (51%) - 14 151 93 3
Not available, N = 248 (49%) - 2 241 - 5
Data are presented in the patients receiving new AT (n = 509) and expressed as number (proportion). AT, antibiotic therapy.
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patients without susceptibility testing (including clinical
deterioration in 16 cases and new site(s) of infection in
6 patients). Among the 80 patients who received a new
AT without microbiologic sampling, only 11 (2%)
changes were made (clinical deterioration in 4 patients,
new site of infection in 2, interruption of aminoglyco-
sides in 3, adverse effects in 2), 17 (29%) changes were
made among the 59 cases who had only identification of
causative organisms and 23 (21%) among the 109
patients with negative cultures.
Appropriateness of new AT
Susceptibility testing and assessment of appropriateness
of a new AT were obtained in 261 (51%) patients homo-
genously distributed throughout the centers. Antibiotic
therapy was judged inappropriate in 58 patients (22%),
involving mainly pneumonia (n = 26; 37.7%), bacteremia
(n = 13; 18.8%), urinary tract (n = 14; 20.3%), and intra-
abdominal infections (n = 13; 18.8%). Among the 215
cases with therapeutic emergencies, susceptibility testing
and assessment of appropriateness was obtained in 126
cases (59%). Antibiotic therapy was considered appropri-
ate in 100 cases (80%).
Patients with appropriate and inappropriate AT had
s i m i l a rS A P SI Is c o r e s( 4 3±1 3v s4 2±1 9 )o na d m i s -
sion to ICU and SOFA scores (7 ± 6 vs 7 ± 5) on initia-
tion of AT. The clinical features at the time of initiation
of AT were assessed in these 261 patients (Table 3).
Some organisms initially considered as contaminants
(coagulase negative staphylococci) or commensals
(enterococci) turned out to be true pathogens. Conse-
quently, the cases were classified at the end the clinical
course as inappropriately treated. The reasons for addi-
tional antibiotic changes not related to susceptibility
testing are shown in Table 3.
Links between new AT and outcome
The mean duration of ICU stay for the whole cohort
was 10.8 ± 9.6 days. A 20% mortality rate (n =1 0 1 )w a s
observed among the 509 patients receiving new AT with
no significant differences according to gender, type of
admission or type of infection (Table 4). No significant
link was evidenced between mortality rate and type of
institution (18% of death in university teaching hospitals
compared to 23% in non-university hospitals (P =0 . 1 7 ) )
or type of ICU (17% of death in surgical ICUs, 19% in
medical ICUs and 23% in medico-surgical ICUs (P =
0.35)). No significant link was evidenced between mor-
tality rate and time of prescription, type of prescriber,
appropriateness of AT or subsequent changes of treat-
ment. Six the 80 patients (7.5%) who received a new AT
without any microbiologic investigation finally died
(including 2 of those who had changes in AT), while
death was reported in 33 (30%) of the 109 cases with
negative samples and 11 (19%) of the 59 patients where
only the organism(s) was identified.
Among the 509 cases, only the progress of 27 (5.3%)
patients was tracked in the ICU for more than 30 days
(6 deaths and 21 survivors). In the three most frequent
sites of infection, mortality rates between patients
receiving appropriate and inappropriate AT were not
significantly different: 24/96 (25%) vs 3/26 (12%), 14/65
(22%) vs 5/15 (33%), 8/46 (17%) vs 3/13 (23%), in pneu-
monia, bacteremia and intra-abdominal infections,
respectively. In contrast, underlying diseases and severity
at the time of initiation of AT were associated with a
higher mortality rate (Table 4).
Among the 98 patients who had AT changed for non-
microbiologic reasons, death was observed in 8/21 (38%)
patients who deteriorated clinically, in 2/14 (14%)
patients who developed a new site(s) of infection, in 3/
36 (8%) of those whose aminoglycosides were stopped
and in 3/40 (7.5%) of those who had de-escalation
therapy.
Among the 126 patients with therapeutic emergencies
in whom appropriateness of AT was assessed, death was
reported in 4 (15%) of the 26 patients who had inap-
propriate AT and 31 (31%) of the 100 patients where
AT was appropriate.
Univariate and multivariate analysis assessed predictive
factors of mortality in the population of patients receiv-
ing new AT (Tables 4 and 5). Hosmer-Lemshow good-
ness of fit Chi square was 5.06, P = 0.75. Among the
identified risks of mortality, the absence of AT protocols
was the only criterion not related to underlying disease
or severity at the time of initiation of AT.
Discussion
To our knowledge, this study represents the largest
cohort addressing the AT decision-making process in
ICU patients. More than 60% of patients received AT
during their ICU stay and one third of them required
new AT initiated out-of-hours in half of the cases.
Observational studies have their own limitations. A
limited number of centers participated in the survey
with heterogeneous activity and case-mix in teaching
and non-teaching institutions. All microbiology labora-
tories followed the same guidelines published by the
French Society of Microbiology [21], decreasing the het-
erogeneity of the management and decision-making pro-
cess. The duration of the study was not sufficient to
take into account seasonal changes in antibiotic pre-
scriptions. In the study design, the decision-making pro-
cess was deliberately addressed rather than
considerations linked to the quality of antibiotic pre-
scription in terms of pharmacokinetic/pharmacodynamic
(pK/pD) parameters or adherence to local protocols.
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with microbiologically appropriate AT could be due to
poor quality of the antibiotic prescription. In addition,
the delay in starting new AT was not documented. This
is a critical point in addressing the issue of relationship
between mortality and AT and admittedly is a weakness
of our study. No distinction was made between commu-
nity-acquired and nosocomial infections. Finally, metho-
dological issues could be considered as limitations. This
is the case for appropriateness of antibiotic therapy
assessed by local investigators, the duration of antibiotic
therapy not determined and hospital mortality not
assessed. Consequently, the results of this study should
be interpreted cautiously, although this descriptive study
can be assumed to reflect “real life” conditions.
In a single-center prospective study, Bergmans et al.
reported that 36% of patients had at least one infection
during their ICU stay and were treated for infection on
48% of all patient-days [14]. In a 15-month study in a
surgical ICU using computerized patient data manage-
ment systems, Hartmann et al. observed that 58% of the
patients received AT [24]. In a single-center prospective
audit, Warren et al. reported that 77% of admissions
received at least one AT during their ICU stay [13]. In
this paper, 17% of AT were initiated prior to ICU
admission and 45% of patients received antibiotics for
suspected or proven sepsis [13]. In a study performed in
23 Swedish ICUs over a two-week period, the median
proportion of patients receiving antibiotics was 74%
(range 24 to 93%); 64% of all prescriptions corresponded
to empiric AT with only minor differences between
units [15]. In a Turkish six-month single-center study,
AT was prescribed in 61% of all admissions and empiric
therapy accounted for 46% of cases [25]. In the EPIC II
study, 9,084 (71%) of 13,796 adult patients in 1,265
ICUs from 75 countries were receiving antibiotics in
this point prevalence study [26].
In more than 70% of our patients receiving AT, treat-
ment was initiated before the results of Gram-stained
direct examination and at the time of direct examination
in more than 90% of these patients. In a prospective
Spanish multicenter study in severe sepsis, the authors
observed that 66% of patients received broad-spectrum
antibiotics during the first six hours after presentation
Table 3 Assessment of the appropriateness of antimicrobial therapy for microbiologically documented infections
Parameter Appropriate AT Inappropriate AT P
(n = 203) (n = 58)
AT protocol available in the ICU 79 (61.1%) 35 (60.3%) 0.91
Timing of new AT prescription
Day shifts 97 (47.8%) 30 (51.7%) 0.59
Out-of-hours 106 (52.2%) 28 (48.3%)
Category of MD prescriber
Fellow 17 (8,4%) 7 (12.1%) 0.88
Senior physician 148 (72.9%) 41 (70.7%)
Medical team decision 38 (18.7%) 10 (17.2%)
Time of initiation of new AT
Suspicion of infection 120 (59.1%) 29 (50.0%)
Gram-stained direct examination available 65 (32.0%) 12 (20.7%) <0.0001
Microbiologic identification available 18 (8.9%) 3 (5.2%)
Susceptibility testing available 0 14 (24.4%)
Change of AT
None 107 (52.7%) 14 (24.1%)
Gram-stained direct examination available 11 (5.4%) 4 (6.9%) 0.001
Microbiologic identification available 32 (15.8%) 11 (19.0%)
Susceptibility testing available 53 (26.1%) 29 (50.0%)
Number of AT changes 0.5 ± 0.6 0.9 ± 0.7 0.05
Non-microbiologic reason for AT change 38 (18.7%) 10 (17.2%) 0.79
Clinical worsening 4 (2.0%) 1 (1.7%)
New site of infection 5 (2.5%) 4 (6.9%)
Aminoglycoside stopped 23 (11.3%) 4 (6.9%)
AB side effect 3 (1.5%) 1 (1.7%)
De-escalation 26 (12.8%) 4 (6.9%)
Data are presented among the patients receiving new AT (n = 509), and expressed as mean ± SD or as number (proportion). AT, antibiotic therapy; ICU, intensive
care unit; MD, medical doctor.
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Page 8 of 13Table 4 Clinical and therapeutic characteristics of the population receiving new antibiotic treatment according to outcome
Parameter Alive Death during ICU stay P
(n = 408) (n = 101)
Age 55 ± 19 66 ± 15 0.001
Underlying diseases
Not ultimately fatal 279 (68.4%) 50 (49.5%) <0.0001
Ultimately fatal 95 (23.3%) 28 (27.7%)
Rapidly fatal 34 (8.3%) 23 (22.8%)
Immunosuppression 43 (10.3%) 18 (17.8%) 0.04
SAPS II score on admission 37 ± 15 56 ± 20 <0.0001
SOFA score at the beginning of AT 6 ± 5 12 ± 6 0.04
Severe hypoxemia 72 (17.6%) 29 (28.7%) 0.01
Septic shock 79 (19.4%) 43 (42.6%) <0.0001
Multiple organ failure 18 (4.4%) 29 (28.7%) <0.0001
AT protocol available 269 (65.9%) 58 (57.4%) 0.11
Number of AT protocols available 4.2 ± 3.5 3.8 ± 3.8 0.24
Category of MD prescriber
Fellow 46 (11.2%) 10 (10%) 0.57
Senior physician 292 (71.6%) 74 (73.1%)
Medical team decision 70 (17.2%) 17 (16.9%)
Time of prescription of new AT
Day shifts 185 (45.3%) 42 (41.6%) 0.49
Out-of-hours 223 (54.7%) 59 (58.4%)
Suspicion of infection 298 (73.0%) 65 (64.4%) 0.27
Gram-stained direct examination available 77 (18.9%) 28 (27.7%)
Microbiologic identification available 20 (4.9%) 5 (5.0%)
Susceptibility testing available 13 (3.2%) 3 (2.9%)
Appropriateness of new AT
Appropriate 160 (39.2%) 43 (42.6%) 0.45
Inappropriate 50 (12.3%) 8 (7.9%)
Not applicable 198 (48.5%) 50 (49.5%)
Change of empiric AB
None 286 (70.1%) 69 (68.3%) 0.65
Gram-stained direct examination available 14 (3.4%) 5 (5.0%)
Microbiologic identification available 40 (9.8%) 13 (12.9%)
Susceptibility testing available 68 (16.7%) 14 (13.8%)
Number of AB changes 0.4 ± 0.6 0.4 ± 0.6 0.67
Data are presented as mean ± SD or as number (proportion). AT, antibiotic therapy; MD, medical doctor; SAPS II, simplified acute physiologic score II; SOFA,
sequential organ failure assessment; Underlying diseases according to the McCabe score, see material and methods section.
Table 5 Univariate and multivariate analysis of predictive factors of mortality
Parameter OR (95%CI) Adjusted OR (95%CI) P-value
Lack of AT protocol 1.4 (0.9 to 2.2) 1.64 (1.01 to 2.69) 0.04
Age ≥60 2.6 (1.6 to 4.1) 1.97 (1.19 to 3.26) 0.008
SAPS II score on admission ≥38 4.5 (2.5 to 7.5) 2.78 (1.60 to 4.84) <0.0001
Rapidly fatal underlying disease 3.2 (1.8 to 5.8) 2.91 (1.52 to 5.56) 0.001
SOFA score at the beginning of AT ≥6 6.2 (3.5 to 10.9) 4.48 (2.46 to 8.18) <0.0001
Immunosuppression 1.8 (1.1 to 3.4) — 0.26
Inappropriate AT 0.6 (0.3 to 1.3) — 0.19
Septic shock 3.1 (1.9 to 4.9) — 0.26
University teaching hospitals 0.7 (0.5 to 1.1) — 0.23
Data are presented in the patients receiving new AT (n = 509). CI, confidence intervals; OR, odds-ratio; Rapidly fatal underlying disease (death <1 year) according
to the McCabe score, see material and methods section; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment; AT, antibiotic
therapy.
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over six months in 2006, the authors reported that anti-
biotic therapy was administered within the first three
and six hours following the diagnosis of severe sepsis or
septic shock in 46% and 61% of patients, respectively
[27]. Other studies addressing the delay of AT have
reported similar observations of treatments administered
within the first three to six hours in 60 to 86% of
patients [8 ,9].
Heterogeneity of practice with regard to microbiologi-
cal sampling was not a surprise. In a previous observa-
tional study addressing the treatment of postoperative
pneumonia, we reported that 14% of the patients
received empiric AT without pulmonary samples having
been taken [28]. While half of these of patients were
hospitalized in ICU at the time of diagnosis only 6% of
them developed ventilator associated pneumonia. These
were mainly the less severe cases. The second major
source for early treatment without sampling was the
absence of round-the-clock microbiological laboratory
facilities. This was not the case in our study where all
ICUs had direct access to the laboratory.
To our knowledge, very few studies have evaluated
whether initiation of AT during out-of-hours modifies
the appropriateness of antimicrobial therapy. We
hypothesized that out-of-hours could be associated with
a lower proportion of appropriate AT, especially among
the least experienced ICU physicians. Interestingly, no
such differences were observed considering appropriate-
ness of AT or outcome. This point was also not
observed in centers without written guidelines. How-
ever, the proportion of fellow prescribers is too small to
draw any conclusions. Inexperienced physicians may
h a v eat e n d e n c yt os t a r tab r o a ds p e c t r u mA Tr e g i m e
and this perhaps explains why no correlation between
level of training and appropriateness was found. Local
protocols and guidelines might play a protective role in
that more antimicrobials are prescribed more securely
by on-call doctors and more often at the beginning of
infection probably ensuring earlier initiation of
treatment.
Defining appropriateness of AT is a major challenge.
This issue can be assessed in many ways. Gyssens et al.
have developed an interesting algorithm to assess com-
prehensively the quality of antibiotic prescriptions [29].
Basing it only on a match between the antibiotic given
and the results of susceptibility testing is the commonest
approach used in the literature and makes sense with
regard to patient outcome in severe infections. However,
this mode of prescribing is perhaps short-sighted. Even
if broad spectrum AT is much more likely to be “appro-
priate” than limited spectrum AT in the circumstances,
the ecologic issues and risks of emergence of resistance
with such a policy are major concerns.
De-escalation following AT appears to vary consider-
ably, depending on the initial diagnosis from 23% of all
antibiotic prescriptions [13] to 64% in patients with sep-
tic shock [4]. However, in many instances, no microbio-
logic confirmation is obtained or susceptibility testing is
not available, which raises the issue of de-escalation.
This has been frequently demonstrated where there is
suspicion of pulmonary infection, as many noninfectious
processes present with lung infiltrates and fever, falsely
attributed to pneumonia [30,31]. In ventilator associated
pneumonia, as many as 30% of clinically suspected cases
are not confirmed microbiologically [32], while in surgi-
cal ICU patients, Singh et al. [33] reported that only
30% of pulmonary infiltrates were the result of pneumo-
nia. De-escalation is, therefore, problematic in these
cases [34] and should be considered cautiously especially
in therapeutic emergencies. In the absence of confirma-
tion of infection (for example, negatives cultures in a
patient already receiving AT), de-escalation is difficult
and the appropriateness can only be evaluated by com-
pliance to the protocols.
The proportions of appropriate AT in ICU patients
are usually situated in the range of 70 to 80% of cases
[1,2,4,9] and up to 89% in some specific diagnoses [4].
The proportion of documented septic episodes was only
slightly greater than 50% in our study and evaluation of
appropriateness was based on documented cases. In the
study by Kumar [5], appropriateness was also evaluated
in non-documented infections by comparing the treat-
ment to local written guidelines.
The absence of a significant link between mortality
and appropriateness of AT is somewhat surprising and
appears to contradict one the findings of the study: the
lack of treatment protocols was an independent risk fac-
tor for increased mortality. An explanation for this para-
dox could be linked to the heterogeneity of the study
population involving an insufficient number of patients
to reach a significant threshold to observe an effect of
inappropriateness. Previous studies demonstrating the
importance of appropriateness from AT usually used
larger cohorts of patients [1,2,5,35] or analyzed selected
populations with a single disease [3,4,35,36]. The role
played by young prescribers might also be considered.
Inexperienced physicians as mentioned earlier may
rather have a tendency to start a broad therapy regime
which might explain why no correlation between level
of training and appropriateness was found. In addition,
the possibility of misdiagnosis cannot be excluded, since
appropriateness of AT did not include this criteria.
Information about delays in initiating AT would also
have been of value in explaining our observations.
Many reports have shown that the use of antimicro-
bial guidelines was associated with improved appropriate
antibiotic use, decreased duration of AT, reduced
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Page 10 of 13antibiotic costs and could decrease mortality, as
observed in hospital-acquired pneumonia [37,38]. The
use of guidelines could be a surrogate marker for a bet-
ter quality of care in general in the ICUs, thereby
explaining the link between availability of guidelines and
prognosis. This point was clearly emphasized in the stu-
dies assessing the effects of implementation of the
guidelines of the surviving sepsis campaign [27,39]. In
view of the limitations of our work, the observations
about the use of guidelines and prognosis should be
considered cautiously. However, it is of interest to
notice that among the risk factors of mortality identified
in our patients, the absence of AT protocols was the
only parameter that could be easily modified, as the
other risk factors were linked to underlying disease or
severity at the time of AT.
In view of our data, almost 20% of antibiotic prescrip-
tions might be unnecessary in patients with suspected
infection. In this setting, antimicrobial stewardship pro-
grams might be useful [40]. Developing protocols in
association with infection control measures could be
considered a first step of improving antibiotic use.
Of all indications for AT, the respiratory tract is by far
the most important site of infection accounting for 47%
of all infections in our cohort, and almost half of these
cases corresponded to severe hypoxemic pneumonia.
These pulmonary infections are the most frequent rea-
son for AT in ICUs, reported in 43 to 51% of cases
[13,14], and up to 60% in a context of septic shock [4]).
The frequency and severity of these cases might justify
large-scale diffusion of local protocols concerning this
specific issue.
Conclusions
In view of the limited number of publications on this
topic, our results should be of interest to clinicians in
the field. Our observations show that more than half of
the patients admitted in ICU received antibiotics during
their stay, half of them on an empiric basis. Half of
these treatments may not be justified on the basis of
negative microbiologic cultures. In ICUs with written
protocols for empiric AT, treatments might be initiated
more rapidly at the time of suspicion of infection and
out-of-hours. These observations should encourage the
establishment of local AT protocols to initiate AT with-
out delay and to stop the abuse of AT. Since pulmonary
infections are the most frequent type of infection and as
septic shock and MOF are the most life-threatening
infections, local guidelines should start by addressing
these issues.
Key messages
￿ More than half of all critical care patients receive
antibiotic therapy during their ICU stay.
￿ Half of the antibiotic treatments administered in
ICUs are initiated on an empiric basis.
￿ Empiric antibiotic prescriptions are more frequent
at the time of suspicion of infection in ICUs with
written protocols
￿ Empiric antibiotic prescriptions are more frequent
out-of-hours in the units with a written protocol
￿ De-escalation therapy and minimizing the abuse of
antibiotic therapies should be discussed comprehen-
sively and accurately.
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